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ABSTRACT
Background Increased subchondral bone turnover may
contribute to pain in osteoarthritis (OA).
Objectives To investigate the analgesic potential of a
modiﬁed version of osteoprotegerin (osteoprotegerin-Fc
(OPG-Fc)) in the monosodium iodoacetate (MIA) model
of OA pain.
Methods Male Sprague Dawley rats (140–260 g) were
treated with either OPG-Fc (3 mg/kg, subcutaneously) or
vehicle (phosphate-buffered saline) between days 1 and
27 (pre-emptive treatment) or days 21 and 27
(therapeutic treatment) after an intra-articular injection of
MIA (1 mg/50 ml) or saline. A separate cohort of rats
received the bisphosphonate zoledronate (100 mg/kg,
subcutaneously) between days 1 and 25 post-MIA
injection. Incapacitance testing and von Frey (1–15 g)
hind paw withdrawal thresholds were used to assess
pain behaviour. At the end of the study, rats were killed
and the knee joints and spinal cord removed for
analysis. Immunohistochemical studies using Iba-1 and
GFAP quantiﬁed levels of activation of spinal microglia
and astrocytes, respectively. Joint sections were stained
with haematoxylin and eosin or Safranin-O fast green
and scored for matrix proteoglycan and overall joint
morphology. The numbers of tartrate-resistant acid
phosphatase-positive osteoclasts were quantiﬁed. N=10
rats/group.
Results Pre-emptive treatment with OPG-Fc
signiﬁcantly attenuated the development of MIA-induced
changes in weightbearing, but not allodynia. OPG-Fc
decreased osteoclast number, inhibited the formation of
osteophytes and improved structural pathology within
the joint similarly to the decrease seen after
pretreatment with the bisphosphonate, zoledronate.
Therapeutic treatment with OPG-Fc decreased pain
behaviour, but did not improve pathology in rats with
established joint damage.
Conclusions Our data suggest that early targeting of
osteoclasts may reduce pain associated with OA.
INTRODUCTION
Pain is one of the ﬁrst symptoms of knee osteoarth-
ritis (OA),1 and often causes increasing disability as
the disease progresses. Treatments for OA pain
have limited efﬁcacy, and joint replacement surgery
is a common outcome.2 3 OA pain arises both from
peripheral nociceptive inputs, and from central sen-
sitisation.4 5 Central sensitisation usually decreases
after total joint replacement surgery,2 indicating
that continuing nociceptive inputs from the joint
may drive central pain mechanisms. Within the
joint, OA pain is associated with subchondral bone
marrow lesions6 and with synovitis (see references
in Sellam and Berenbaum7). Several existing treat-
ments may partially alleviate OA pain by reducing
synovitis, but only recently has the analgesic poten-
tial of targeting subchondral bone attracted
attention.
OA is associated with an initial increase in sub-
chondral bone resorption and resultant thinning of
the subchondral plate, followed by subchondral
sclerosis and osteophyte formation.8 Changes in
subchondral bone turnover precede changes in car-
tilage (see references in Kwan Tat et al9) and pain-
related molecules have been detected in OA sub-
chondral bone.10 Dynamic changes in bone turn-
over result from increased activity of osteoclasts and
osteoblasts, and the osteoprotegerin (OPG)/receptor
activator of NF-κB (RANK)/receptor activator of
NF-κB ligand (RANKL) system is critical for this
activity.9 11 12 Osteoclast activation is associated
with reduced extracellular pH, and release of pro-
teases. In addition to increasing bone resorption,
osteoclast products can activate and sensitise periph-
eral nerves and increase pain signalling.13
Furthermore, subchondral osteoclasts cut channels
through the osteochondral junction (OCJ), and this
loss of osteochondral integrity may expose subchon-
dral nerves to algesic factors produced by the syno-
vium and articular cartilage.14 Bisphosphonates,
which inhibit bone resorption, increase trabecular
bone thickness, and may attenuate bone marrow
lesions and knee pain,15 supporting the hypothesis
that increased subchondral bone turnover may con-
tribute to OA pain. The beneﬁcial effects of stron-
tium ranelate on structural changes and pain in
patients with OA, further support a contribution of
bone turnover to OA progression.16
As in human OA, both surgical17 and the mono-
sodium iodoacetate (MIA)18–20 models of OA in
the rodent exhibit excessive osteoclast activity and
bone remodelling. Chronic bisphosphonate treat-
ment inhibits osteoclast number, bone resorption
and structural changes17 20 in these models and a
canine model21 of OA. Importantly, chronic pre-
emptive treatment with zoledronate attenuated
both the pathological features of OA and the
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development of pain behaviour.20 A recent clinical trial indi-
cated reduced OA knee pain after treatment with strontium
ranelate, an effect that may be mediated through reduced bone
turnover.16 The analgesic effects of bisphosphonates or stron-
tium in patients with OA, however, are relatively weak,15 16 22
and more potent or speciﬁc inhibitors of subchondral bone
turnover may have greater analgesic potential in OA.
OPG is a soluble member of the tumour necrosis factor super-
family which sequesters RANKL and puts a brake on osteoclast
formation (see references in Kwan Tat et al9). An imbalance in
the OPG/RANKL system, both in synovial ﬂuid and serum, has
been associated with OA severity in man.12 23 Exogenous treat-
ment with a modiﬁed OPG (OPG-Fc) attenuates bone loss in a
rodent model of inﬂammatory arthritis24 and, although effects
on arthritis pain were not reported, OPG inhibited bone cancer-
induced pain behaviour.25 We hypothesised that OPG-Fc could
prevent the development of pain behaviour in a model of OA
pain by inhibiting osteoclastogenesis and reducing early bone
turnover in the joint. We therefore compared the effects of pre-
emptive and therapeutic OPG on pain and joint pathology in a
model of OA.
METHODS
Studies were conducted in accordance with UK Home Ofﬁce
Animals (Scientiﬁc Procedures) Act (1986) and guidelines of the
International Association for the Study of Pain. One hundred and
four male Sprague Dawley rats (Charles River UK) weighing
140–260 g (5–7 weeks old) were used. An overview of the
experimental design and the group sizes is provided in online
supplementary ﬁgure S1 and online supplementary table S1. Rats
were brieﬂy anaesthetised with isoﬂurane (3% in 1 l/min O2).
Joint damage was induced by a single intra-articular injection of
MIA (1 mg/50 μl; Sigma UK) in saline through the infrapatellar
ligament of the left knee. OA develops in response to a variety of
insults to the joint. Intra-articular MIA disrupts glycolysis result-
ing in chondrocyte death,26 which is believed to be the primary
insult in our model. Control animals received a single injection
of saline (50 μl) into the left knee. Two separate measures of pain
behaviour were assessed: change in hind limb weight distribu-
tion, which is a behavioural correlate of hyperalgesia, and hind
paw mechanical withdrawal thresholds, which provide an index
of central sensitisation. Changes in hindlimb weight distribution
and hindpaw mechanical withdrawal thresholds were measured
before intra-articular injection (day 0, baseline) and then from
day 3 onwards.27 Weight distribution was assessed using an inca-
pacitance tester (Linton Instrumentation, UK) and paw with-
drawal thresholds (PWTs) were assessed using von Frey
monoﬁlaments (Semmes–Weinstein monoﬁlaments of bending
forces 1–15 g).28 Under isoﬂurane anaesthesia (1.5–2% in 66%
N2O−33% O2), neuropathic rats received tight ligation of spinal
nerves L5 and L6 with 6–0 silk thread, as previously described.29
Sham rats had nerves exposed but not ligated. PWTs were
assessed as above, before surgery and then from day 2 to 14.
Drug administration
A modiﬁed version of OPG (consisting of the RANKL-binding
portion of OPG linked with the constant (Fc) domain of IgG24),
OPG-Fc, was a gift from Amgen Ltd and was diluted to 3 mg/ml.
Zoledronate tetrahydrate (Toronto Research Chemicals) was
made up as a 100 μg/ml solution. Rats were randomised in the
treatment protocol, with the tester blind to both drug and injury.
Dosing regimens were based on pharmacokinetics and previous
evidence of efﬁcacy in rodent models for each of OPG-Fc24 and
zoledronate.20
Pre-emptive OPG-Fc
Subcutaneous injections of OPG-Fc (3 mg/kg) or vehicle
(phosphate-buffered saline (PBS)) were given every other day
from days 1 to 27 post-MIA injection. Saline-treated rats
received vehicle.
Pre-emptive zoledronate
Subcutaneous injections of zoledronate (100 mg/kg) or vehicle
(PBS) were given every third day from days 1 to 25 post-MIA
injection, according to Strassle et al.20 Saline-treated rats
received vehicle.
Therapeutic OPG-Fc
Subcutaneous injections of vehicle were given every other day
from days 1 to 20 post-MIA injection. On day 21 rats received
either OPG-Fc (3 mg/kg) or vehicle (PBS) every other day until
day 27. Rats were stratiﬁed according to their pain behaviour
before drug treatment (days 14 and 16).
Histology
At the end of the pharmacological study, rats were killed by
anaesthetic overdose and tissues were ﬁxed by transcardiac per-
fusion with 4% paraformaldehyde solution. Tibiofemoral joints
were removed and post-ﬁxed in neutral buffered formalin (con-
taining 4% formaldehyde), decalciﬁed in EDTA and processed
as previously described.30 Mid-coronal tissue sections (5 μM)
were stained for evaluations and all histomorphometry was by
an observer blinded to the treatment groups. Lumbar spinal
cords were post-ﬁxed in paraformaldehyde, as previously
described.28
Joint structure and inﬂammation
Haematoxylin and eosin or Safranin-O/fast green-stained sec-
tions were scored for matrix proteoglycan and overall joint
morphology.31 32 Cartilage surface integrity was scored from
0 (normal) to 5 (full-thickness degeneration), and a total joint
damage score (range 0–15) was calculated as cartilage surface
integrity × length of cartilage involved in thirds. Osteophyte
scores ranged from 0 (no osteophyte) to 3 (osteophyte
>160 mm). The integrity of the OCJ was measured as the
number of channels crossing the OCJ into the cartilage of the
whole section of medial tibial plateau. Proteoglycan loss was
evaluated on a scale from 0 (normal proteoglycan staining) to 4
(complete loss of proteoglycan staining). Chondrocyte appear-
ance was graded from 0 (normal appearance and density), to 3
(chondrocyte hypocellularity). Synovial inﬂammation was
graded as previously described33 on a scale from 0 (lining cell
layer 1–2 cells thick) to 3 (lining cell layer >9 cells thick and/or
severe increase in cellularity).
Osteoclast numbers
Tissue sections were dewaxed and recalciﬁed before
tartrate-resistant acid phosphatase (TRAP) staining using the
commercially available kit (Sigma-Aldrich, UK). The number of
TRAP-positive multinucleated osteoclasts was quantiﬁed within
the subchondral bone area comprising the area between the car-
tilage/bone junction and the growth plate following the standard
convention.34
Quantiﬁcation of glial activation in the spinal cord
Microglial cells were stained using Iba-135 and astrocytes were
stained using glial ﬁbrillary acidic protein (GFAP),36 as previ-
ously described.28 Total numbers of positively identiﬁed
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activated microglia expressing Iba-1 were counted manually in
both ipsilateral and contralateral quadrants of individual 40 mm
sections. For quantiﬁcation of GFAP, images of the superﬁcial
dorsal horn of the spinal cord were captured using a ×40
objective lens. All image analysis, cell counts and ﬂuorescence
measurements were performed as previously described.28
Statistical analyses
For all comparisons, p<0.05 was taken to indicate statistical sig-
niﬁcance. Statistical comparisons between groups were carried
out using a two-way analysis of variance or Kruskal–Wallis tests
with post hoc t tests, Dunnett’s or Mann–Whitney tests, as
appropriate. Bonferroni corrections were used for multiple com-
parisons. Data are presented graphically as means (±SEM).
RESULTS
Pre-emptive treatment with OPG-Fc reduced pain behaviour
and pathology in osteoarthritic rats
Consistent with previous studies, MIA-treated rats which
received vehicle exhibited a decrease in ipsilateral weightbearing
and hind PWTs from day 3 post-MIA injection, which was main-
tained throughout the study and was signiﬁcant compared with
saline-injected rats (ﬁgure 1A,B). At 28 days post-MIA injection,
there was an increase in the number of TRAP-positive osteoclasts
in the tibial plateau (ﬁgure 1C), increased synovial inﬂammation,
cartilage damage and osteophyte formation, compared with
saline-injected rats (ﬁgures 1D–F and 2). Intra-articular injection
of saline was not associated with pain behaviour (ﬁgure 1A,B),
nor changes in joint structure (ﬁgures 1D–F and 2). Pre-emptive
systemic OPG-Fc signiﬁcantly attenuated the development of
MIA-induced changes in weightbearing from day 16 onwards,
compared with vehicle administration in MIA-treated rats (ﬁgure
1A). Pre-emptive OPG-Fc did not signiﬁcantly alter
MIA-induced decreases in hind PWTs (ﬁgure 1B). Pre-emptive
systemic OPG-Fc signiﬁcantly decreased the number of
TRAP-positive osteoclasts (see online supplementary ﬁgure S2) in
the tibial plateau, synovitis, cartilage damage and osteophyte for-
mation in MIA-treated rats, compared with vehicle treatment
(ﬁgures 1C–F and 2). However, neither pre-emptive nor thera-
peutic treatment with OPG-Fc signiﬁcantly altered the
MIA-induced increase in the number of channels crossing the
OCJ, nor did these treatments alter the extent of MIA-induced
loss of proteoglycan or the chondrocyte appearance (table 1,
ﬁgure 2, see online supplementary ﬁgure S3).
In contrast to the marked effects of pre-emptive OPG-Fc
treatment on MIA-induced changes in weightbearing, synovitis,
osteophytosis and aspects of cartilage damage, there was no evi-
dence that this treatment alters spinal mechanisms of central
sensitisation. At 28 days post-MIA injection, there was a signiﬁ-
cant increase in the number of Iba-1-positive microglia and the
level of GFAP immunoﬂuorescence, indicative of reactive astro-
cytes, in the ipsilateral dorsal horn of MIA-treated rats which
received pre-emptive vehicle (36.92±3.5 Iba-1-positive micro-
glia, GFAP immunoﬂuorescence: 36.56±0.7 mean grey intensity
value AU) compared with saline-injected controls (21.46±1.8
Iba-1-positive microglia, GFAP immunoﬂuorescence: 24.57±2.5
mean grey intensity value AU). Pre-emptive systemic OPG-Fc
did not signiﬁcantly alter the expression of these markers of
central sensitisation (31.63±1.9 Iba-1-positive microglia, GFAP
immunoﬂuorescence: 35.45±1.0 mean grey intensity value AU)
in MIA-injected rats. To consolidate the evidence that the effects
of pre-emptive treatment with OPG-Fc were speciﬁc to joint
pain, rather than a generalised anti-nociceptive effect, the effect
of OPG-Fc in another model of chronic pain was evaluated.
Pre-emptive treatment with OPG-Fc did not signiﬁcantly alter
the decrease in hind PWTs in neuropathic rats (see online sup-
plementary ﬁgure S4).
Pre-emptive treatment with zoledronate reduced pain
behaviour and pathology in osteoarthritic rats
In the next series of experiments we sought to further
strengthen the association between subchondral bone turnover
and changes in weightbearing in this model of OA. Pre-emptive
systemic zoledronate signiﬁcantly attenuated the MIA-induced
changes in weightbearing compared with vehicle-treated MIA
rats (ﬁgure 3A). Zoledronate produced an elevation in hind
PWTs in MIA-treated rats compared with vehicle-treated MIA
rats, but this did not reach signiﬁcance (ﬁgure 3A). There was
no effect of zoledronate on the number of TRAP-positive osteo-
clasts in the tibial plateau in MIA-treated rats (ﬁgure 3A).
Zoledronate signiﬁcantly inhibited the development of synovitis,
cartilage pathology and osteophyte formation compared with
vehicle administration in MIA-treated rats (ﬁgure 3D–F).
Zoledronate signiﬁcantly decreased the MIA-induced increase in
the number of channels crossing the OCJ (table 1), but, consist-
ent with OPG-Fc, zoledronate did not alter the MIA-induced
proteoglycan loss or the chondrocyte appearance (table 1).
Therapeutic treatment with OPG-Fc
Finally, the therapeutic effects of OPG-Fc once the model of
OA pain is established were determined. Before intervention,
MIA-treated rats developed changes in weightbearing and hind
PWTs at similar rates and magnitudes as the earlier experimental
groups (ﬁgure 4A,B). Therapeutic OPG-Fc from day 21 to 27
signiﬁcantly inhibited any further decreases in weightbearing on
the ipsilateral hindlimb, compared with vehicle treatment, but
did not reverse the decrease in weightbearing exhibited before
OPG-Fc intervention (ﬁgure 4A). Therapeutic OPG-Fc did not
alter changes in hind PWTs in MIA-treated rats (ﬁgure 4B).
Therapeutic OPG-Fc signiﬁcantly reduced the number of osteo-
clasts in the ipsilateral knee joint, compared with vehicle-treated
MIA rats, but did not signiﬁcantly alter the extent of synovial
inﬂammation, cartilage pathology or osteophyte number at day
28 (ﬁgure 4C–F, see online supplementary ﬁgure S3).
DISCUSSION
Here we demonstrate for the ﬁrst time that a modiﬁed form of
the endogenous inhibitor of RANKL, OPG-Fc, which attenuates
osteoclastogenesis, decreases the number of subchondral osteo-
clasts and inhibits the development of pain behaviour (weight-
bearing asymmetry) and aspects of joint pathology in the MIA
model of OA pain. OPG-Fc treatment did not alter
MIA-induced changes in hind PWTs (distal allodynia).
Therapeutic treatment with OPG-Fc, over a relatively short
period of time, prevented further changes in weightbearing
asymmetry and attenuated osteoclast number but not other
structural changes within the joint. Differences in the effects of
pre-emptive versus therapeutic OPG-Fc on weightbearing asym-
metry and structural changes within the joint suggest that this
treatment may preferentially ameliorate early structural progres-
sion and pain associated with OA.
Pain is the main clinical symptom of OA, and may result from
both increased nociceptive input from the joint, and sensitisa-
tion within the spinal cord and brain. Pathology within a
number of joint structures, including the highly innervated sub-
chondral bone and synovium14 is likely to drive nociceptive
inputs associated with OA. Our ﬁndings that OPG-Fc reduced
the number of subchondral osteoclasts, chondropathy and
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osteophyte formation in the MIA model of OA lead us to
suggest that effects of OPG-Fc on pain behaviour may be
mediated by peripheral effects within the joint. As discussed
earlier, the primary insult in the MIA model is chondrocyte
death, and further work would be required to determine
whether our ﬁndings can be generalised to OA induced by other
factors.
Distal allodynia (decreased hindpaw mechanical withdrawal
thresholds) and the activation of spinal neuroimmune cells are
each indicative of altered spinal processing of sensory inputs and
central sensitisation in MIA-treated rats.28 These changes parallel
evidence of abnormal central pain processing in human OA.5
OPG-Fc did not reduce numbers of activated neuroimmune cells
in the spinal cord in the MIA model of OA pain, and did not
signiﬁcantly decrease distal allodynia. By contrast, pre-emptive
and therapeutic treatment with a non-steroidal anti-inﬂammatory
drug reduced weightbearing asymmetry, distal allodynia and
spinal gliosis in this model of OA pain,28 demonstrating the
importance of a peripheral and central site of action, in particular
once OA pain and structural changes to the joint are established.
Pre-emptive OPG-Fc treatment did not signiﬁcantly alter
mechanical allodynia either in the model of OA or in a model
of neuropathic pain, further suggesting that the effects of
OPG-Fc are predominantly mediated by a peripheral site of
action. This is in contrast to the inhibitory effects of OPG on
neuroimmune cell activation in the spinal cord in a model of
bone cancer pain.25 Differences in the effects of OPG on spinal
sensitisation mechanisms possibly reﬂect distinct pain
Figure 1 Pre-emptive treatment with osteoprotegerin (OPG)-Fc signiﬁcantly attenuates monosodium iodoacetate (MIA)-induced changes in
(A) weightbearing, but not (B) mechanical allodynia and is accompanied by a signiﬁcant reduction in (C) osteoclast number, (D) synovial
inﬂammation (E) cartilage damage and (F) osteophyte number. Statistical comparison between groups was carried out using a two-way analysis of
variance (A) or Kruskal–Wallis test (B) *p<0.05, **p<0.01, ***p<0.001 for MIA-vehicle versus saline-vehicle, ++p<0.01, +++p<0.001 for MIA-OPG
versus saline-vehicle, #p<0.05, ###p<0.001 for MIA-OPG versus MIA-vehicle. (C–F) Statistical comparison comparing groups were performed using a
Kruskal–Wallis test *p<0.05, ***p<0.001. All data are presented as mean±SEM, n=10 rats per group. For osteoclast numbers six sections for each
rat were quantiﬁed and data are presented as mean±SEM. PBS, phosphate-buffered saline; TRAP, tartrate-resistant acid phosphatase.
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mechanisms associated with these two types of bone patholo-
gies. Clinical beneﬁts of joint replacement surgery indicate that
peripheral mechanisms are particularly important in OA pain,
highlighting the potential for relieving OA pain by treatments
directed at the joint itself.
The attenuation of MIA-induced synovitis by pre-emptive
OPG-Fc is consistent with osteoclasts modifying the biochemical
environment of peripheral nerve terminals within the subchon-
dral bone. Indeed, the active resorption of bone by osteoclasts is
achieved by maintaining an acidic extracellular environment at
the osteoclast/bone interface, which probably activates acid
sensing channels, and sensitises other pro-nociceptive/inﬂamma-
tory cation channels such as TRPV1 expressed by primary affer-
ent nociceptors innervating the subchondral bone (see
references in Jimenez-Andrade et al13; Nagae et al37). Given
that synovitis is associated with OA pain clinically, the reduction
in MIA-induced synovitis by pre-emptive OPG-Fc may contrib-
ute to its effects on pain behaviour in our study. Once the
model was established, a relatively short (7 days) treatment with
OPG-Fc did not alter synovial inﬂammation, suggesting that the
Figure 2 Pre-emptive osteoprotegerin (OPG)-Fc attenuates the development of histopathological changes in the knee joints of monosodium
iodoacetate (MIA)-treated rats. Non-arthritic saline injected control rats (A–C) showed normal synovia, with 1–2 cell thick synovial lining (A; arrows),
normal smooth cartilage and joint margins (B-C; arrows) with normal chondrocyte distribution and proteoglycan staining (C). Fewer channels
(asterisks) crossing the osteochondral junction (black line) were seen in these animals (C). MIA-injected rats (D–F) had thicker synovial lining
(arrows) and increased cellularity throughout the synovia (D). Severe cartilage loss and osteophyte growth (circle) at joint margin (E and F)
accompanied with chondrocyte hypocellularity and severe loss of proteoglycan staining as well as increased number of channels (asterisks) crossing
the osteochondral junction were seen in these animals (F). OPG-Fc treated arthritic rats (G–I) had normal synovial cellularity (G; arrows) with smooth
articular cartilage (I; arrows) and less pronounced osteophytes at joint margins (H). Nevertheless, chondrocyte hypocellularity, proteoglycan loss and
channels entering the cartilage in OPG-Fc-treated arthritic rats (I) were comparable to MIA-injected rats (F). Coronal sections stained with
haematoxylin and eosin (synovia: A, D, G, joint: B, E, H) and Safranin-O (C, F, I) stains. Bars=100 mm.
Table 1 Effects of OPG-Fc or zoledronate on the number of channels in the osteochondral junction (OCJ) in the medial tibial plateaus (MTPs),
chondrocyte appearance and proteoglycan loss in MIA-treated rats compared with MIA-vehicle-treated and saline-treated rats.
Pre-emptive OPG Therapeutic OPG Pre-emptive zoledronate
Saline-vehicle MIA-vehicle MIA-OPG MIA-vehicle MIA-OPG Saline-vehicle MIA-vehicle MIA-zoledronate
Number of channels crossing the OCJ in
MTP
4±0.4 8±1 7±2 7±1 6±0.4 1±0.3 7±1*** 3±0.6*+
Chondrocyte appearance score 0.3±0.2 2±0.3** 3±0.2*** 3±0.3 2±0.3 0±0 3±0*** 3±0.2***
Proteoglycan loss grade 1.2±0.3 3±0.4* 3±0.3* 4±0 4±0 0.3±0.2 4±0.2*** 3±0.2***
Statistical analysis was performed with a Kruskal–Wallis test.
*p<0.05, **p<0.01, ***p<0.001 versus saline-vehicle; +p<0.05 versus MIA-vehicle.
Data are expressed as mean±SEM per section.
MIA, monosodium iodoacetate; OPG, osteoprotegerin.
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effects of pre-emptive OPG-Fc on synovitis may be indirect—
for example, via an attenuation of subchondral bone turnover
or cartilage pathology.
The inhibitory effects of pre-emptive treatment with the
bisphosphonate zoledronate reported herein are broadly com-
parable to those previously published,20 with reduced OA struc-
tural damage and pain behaviour evident. Furthermore, as with
OPG-Fc, zoledronate pretreatment signiﬁcantly attenuated
weightbearing asymmetry, but less so distal allodynia. The
precise mechanisms by which structural pathology may mediate
OA pain remain uncertain, both in man and in animal models.
Pain progression in OA is accompanied by an early bone loss,
followed by a later sclerosis of the subchondral bone plate (see
references in Kwan Tat et al9). Increased subchondral uptake of
radiolabelled bisphosphonates38 and MRI-deﬁned bone marrow
lesions6 are each associated with OA pain, and subchondral
osteoclast numbers are increased in OA both in man10 and
rats.20 39 Subchondral bone pathology may contribute to cartil-
age damage in OA (see references in Zhang et al40).
Furthermore, osteophytes are innervated by sensory nerves ori-
ginating in the subchondral bone, and may be a source of OA
pain.41 Our data suggest that effects on structural factors such
as synovitis, cartilage damage and osteophytosis may contribute
to the inhibitory effects of OPG-Fc and zoledronate on pain
behaviour in our model. However, reductions in pain behaviour
occurred despite persistently abnormal proteoglycan staining
Figure 3 Pre-emptive treatment with zoledronate (Zol) signiﬁcantly attenuates monosodium iodoacetate (MIA)-induced changes in
(A) weightbearing, but not (B) mechanical allodynia with no change in (C) osteoclast number, but signiﬁcant reductions in (D) synovial inﬂammation
(E) cartilage damage and (F) osteophyte number. (A and B) Statistical comparison between groups was carried out using a two-way analysis of
variance (A) or Kruskal–Wallis test (B) where *p<0.05, **p<0.01, ***p<0.001 for MIA-vehicle versus saline-vehicle, +p<0.05 for MIA-zoledronate
versus saline-vehicle, #p<0.05, ##p<0.01, ###p<0.001 for MIA-zoledronate versus MIA-vehicle. (C–F) Statistical comparison comparing groups were
performed using a Kruskal–Wallis test *p<0.05, **p<0.01, ***p<0.001. All data are presented as mean±SEM, n=10 rats per group. For osteoclast
numbers six sections for each rat were quantiﬁed and data are presented as mean±SEM. PBS, phosphate-buffered saline.
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and chondrocyte appearance. Therefore preventing these patho-
logical features may not be necessary to relieve pain, at least in
the short term.
The reduction in the numbers of osteochondral channels by
zoledronate treatment in this study was similar to previous
reports,20 although the lack of effect of OPG-Fc treatment on
osteochondral channel number suggests that maintaining osteo-
chondral integrity is not a primary mechanism underlying the
analgesic effects of OPG-Fc in the MIA model of OA pain.
Osteophyte scores used in our study were based on size, includ-
ing cartilaginous surface, and further research would be needed
to investigate effects of OPG-Fc on osteophyte ossiﬁcation. Our
ﬁndings provide a foundation for future more detailed histo-
morphometric42 or micro-CT studies that would explore other
aspects of articular and subchondral bone structure that may
mediate pain but could not be measured in this study. It seems
likely that the effects of OPG-Fc and zoledronate on pain
behaviour, cartilage damage and synovial inﬂammation may not
be attributable to a single mechanism within the subchondral
bone.
In conclusion, our data suggest that the early targeting of
osteoclast turnover may reduce OA pain as demonstrated in the
MIA model of OA pain. Single doses of OPG-Fc and bispho-
sphonates, based on the literature, have been explored in this
study, and other modulators of osteoclasts may also have anal-
gesic potential.16 Although OPG is upregulated in human
OA,11 43 this does not appear sufﬁcient to prevent the increased
osteoclastogenesis seen clinically. Our data in a model of OA
pain suggest that mechanisms contributing to subchondral bone
turnover may be particularly important during the early stages
Figure 4 Therapeutic treatment with osteoprotegerin (OPG)-Fc signiﬁcantly attenuates the further development of changes in (A) weightbearing,
but not (B) mechanical allodynia in rats with established monosodium iodoacetate (MIA)-induced joint pathology, which was accompanied by a
reduction in (C) osteoclast number. There was no effect on (D) synovial inﬂammation (E) cartilage damage and (F) osteophyte number. (A and B)
Statistical comparison between groups was carried out using a two-way analysis of variance (A) or Kruskal–Wallis test (B) *p<0.05, **p<0.01,
***p<0.001 for MIA-vehicle versus saline-vehicle, +p<0.05, ++p<0.01 for MIA-OPG versus saline-vehicle, #p<0.05, ###p<0.001 for MIA-OPG versus
MIA-vehicle. (C–F) Statistical comparison comparing groups was performed using a Mann–Whitney test. All data are presented as mean±SEM, n=10
rats per group. For osteoclast numbers six sections for each rat were quantiﬁed and data are presented as mean±SEM.
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of OA, and that clinical trials of treatments targeting osteoclast
mechanisms are more likely to be successful in early, rather than
late, stages of the disease.
Correction notice This article has been corrected since it was published Online
First. The ﬁrst sentence in the Methods section of the abstract has been corrected.
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